EGFR and colorectal carcinoma: Thus, anti-EGFR antibody treatment was effective for KRAS-wild Caco-2 cells, but single-drug therapy of cetuximab was not sufficient to achieve a therapeutic outcome on KRAS-mutant CRC cells.